Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PHY906 · 1 trial · 1 indication
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
| Arm | Type | Description |
|---|---|---|
| PHY906 Administration | EXPERIMENTAL | PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m\^2 days 1-7 of a 14-day cycle |
| Name | Type | Description |
|---|---|---|
| Capecitabine | DRUG | - |
| PHY906 | DRUG | - |
Inclusion Criteria: * Men or women ≥18 years of age with either a histologic or cytologic diagnosis of locally advanced or metastatic pancreatic adenocarcinoma. However, patients with other solid malignancies will be allowed to participate during the dose escalating Phase I part of the study, who h...
Top 20 of 63 competitors